New Sanofi boss Brandicourt restructures global business
pharmafile | July 16, 2015 | News story | Sales and Marketing | Oliver Brandicourt, Sanofi
Sanofi is reorganising its pharmaceuticals division to create three new business units from January 2016.
Chief executive Oliver Brandicourt has begun to exert his style and influence over the company following his appointment as a replacement for ousted former boss Chris Viehbacher, by making what he described as ‘necessary changes’ to the company’s structure.
The new business units are: general medicines and emerging markets, specialty care, diabetes and cardiovascular, whilst Sanofi Pasteur and Merial remain the same and will continue to manage the current portfolios of vaccines and animal health products.
The general medicines and emerging markets global business unit will be led by Peter Guenter and will consist of Sanofi’s established products, generics, consumer healthcare, and all pharmaceutical businesses in emerging markets.
Its specialty care global business unit is to be re-named Sanofi Genzyme, led by David Meeker, and will contain Sanofi’s medicines in rare diseases, multiple sclerosis, oncology and immunology.
The diabetes and cardiovascular global business unit will be led by Pascale Witz and will consist of Sanofi’s diabetes medicines as well as cardiovascular, including Praluent (alirocumab), which is currently under review by the FDA and the EMA.
Brandicourt is confident in achieving significant growth potentially launching up to six new medicines in 2015 and approximately one new medicine every six months between 2016 and 2018.
Brandicourt says: “The new organisation simplifies and focuses Sanofi to optimise growth. This is a necessary step for ensuring that Sanofi’s new medicines and vaccines continue to build on our heritage of providing innovative healthcare therapies.”
Yasmita Kumar
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
